| Literature DB >> 35747640 |
Michael F Masaracchio1, Kaitlin Kirker1, Parisa Loghmani1, Jillian Gramling1, Michael Mattia2, Rebecca States1.
Abstract
Purpose: To assess the prevalence of tibiofemoral (TF) osteoarthritis (OA) following arthroscopic partial meniscectomy (APM) with a minimum follow-up of 5 years, to explore the prevalence of symptomatic TF OA, and to identify potential risk factors for the development of TF OA following APM.Entities:
Year: 2022 PMID: 35747640 PMCID: PMC9210380 DOI: 10.1016/j.asmr.2022.02.007
Source DB: PubMed Journal: Arthrosc Sports Med Rehabil ISSN: 2666-061X
Fig 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
Description of Studies
| Study | Patient Characteristics | Meniscectomy Compartment | Follow-up | Radiologic Classification System | Radiologic Views | Pre-existing TF OA |
|---|---|---|---|---|---|---|
| Andersson-Molina et al., 2002, | n = 18 | Medial: 17 | 14y (12-15y) | Fairbank and Ahlbäck | WB flexion AP | No |
| Benedetto and Rangger, 1993, | n = 87 | Medial: 70 | 6.3 y (5.8-7.2 y) | Fairbank | WB AP and lateral | No |
| Bolano and Grana, 1993, | n = 50 | Medial: 33 | 5.6 y | Fairbank | WB AP | Yes – grade 1 changes |
| Bonneux and Vandekerckhove, 2002, | n = 29 | Lateral: 29 | 8 y (1.5 y) | Fairbank | WB 45° flexion PA | No |
| Burks et al., 1997, | n = 111 | Medial: 114 | 14.7 y (13.8-16.4 y) | Fairbank | WB AP and PA | No |
| Chatain et al., 2001, | n = 317 | Medial: 317 | 11.5 y (10-15 y) | Radiological IKDC grade | WB 30° flexion AP and monopodal WB extension AP | No |
| Englund and Lohmander, 2004, | n = 48 | Medial: NA | (15-22 y) | Kellgren-Lawrence | WB 15° flexion AP | Yes – grade 1 and 2 |
| Fauno and Nielsen, 1992, | n = 136 | Medial: 117 | 8.5 y (7.9-11.6) | Fairbank | WB AP and lateral | No |
| Han et al., 2010, | n = 46 | Medial: 46 | 6.5 y (5-8.6 y) | Outerbridge | WB 45° flexion PA | Yes – Grade 1 and 2 |
| Higuchi et al., 2000, | n = 67 | Medial: 37 | 12.2 y (10-16 y) | Fairbank | WB AP and lateral | Yes – Grade 1 and 2 |
| Jaureguito et al., 1995, | n = 31 | Lateral: 31 | 8 y (5.5-11.3 y) | Fairbank | WB AP and lateral | Yes – Grade 1 and 2 |
| Kim et al., 2020, | n = 114 | Medial: 114 | 8.3 y (2.8 y), (5-15 y) | Kellgren-Lawrence | WB 45° of flexion PA and AP | Yes – Grade 1 and 2 |
| Lamplot et al., 2019, | n = 44 | Medial: 44 | 6.2 y (0.4 y), (5.6-8.0 y) | Kellgren-Lawrence | WB AP and lateral | Yes – Grade 1 and 2 |
| Lizaur-Utrilla et al., 2019, | n = 258 | Medial: 210 | 5y | Kellgren-Lawrence | WB AP and lateral | Yes – Grade 1 |
| Longo et al., 2019, | n = 57 | Medial: 38 | 8.1 y (5.1-12.1 y) | Kellgren-Lawrence | WB AP and lateral | Yes – Grade 1 |
| Lutz et al., 2015, | n = 22 | Medial: NA | 10.6 y (10-13 y) | Kellgren-Lawrence | WB AP and lateral | Yes – Grade 1 and 2 |
| Maletius et al., 1996, | n = 40 | Medial: 30 | 12-15 y | Fairbank and Ahlbäck | WB 30° flexion AP and lateral | Yes – Grade 1 and 2 |
| Rockborn and Gillquist, 1995, | n = 43 | Medial: 24 | 13 y (11-15 y) | Ahlbäck | WB slightly flexed AP | Yes – Grade 1 |
| Scheller et al., 2001, | n = 75 | Lateral: 75 | 8.7 y (5-15 y) | Fairbank | WB AP and lateral | No |
| Sommerlath, 1991, | n = 25 | Medial: 17 | 7 y (6-10 y) | Fairbank and Ahlbäck | WB 30° flexion | No |
| Stein et al., 2010, | n = 20 | Medial: 20 | 9.2 y (2.6 y) | Fairbank | WB AP and lateral | Yes – Grade 1 and 2 |
| Vautrin and Schwartz, 2016, | n = 34 | Medial: 23 | 22.6y | Ahlbäck | WB AP and lateral | No |
AP, anterior to posterior; F, female; M, male; NA, not available; OA, osteoarthritis; PA, posterior to anterior; TF, tibiofemoral; WB, weight-bearing.
Age is reported as mean ± standard deviation and/or range across all study subjects who received arthroscopic partial meniscectomy unless otherwise indicated.
Follow-up time periods are reported as the mean ± standard deviation and/or range after surgery unless otherwise indicated.
Risk of Bias Assessment
| Study | Question Number | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Total | |
| Andersson-Molina et al., 2002 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 7 |
| Benedetto and Rangger, 1993 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 9 |
| Bolano and Grana, 1993 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 7 |
| Bonneux and Vandekerckhove, 2002 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 7 |
| Burks et al., 1997 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 7 |
| Chatain et al., 2001 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 10 |
| Englund and Lohmander, 2004 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 9 |
| Fauno and Nielsen, 1992 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 9 |
| Han et al., 2010 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 7 |
| Higuchi et al., 2000 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 10 |
| Jaureguito et al., 1995 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Kim et al., 2020 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 10 |
| Lamplot et al., 2019 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 9 |
| Lizaur-Utrilla et al., 2019 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 10 |
| Longo et al., 2019 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 9 |
| Lutz et al., 2015 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 10 |
| Maletius et al., 1996 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 9 |
| Rockborn and Gillquist 1995 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 7 |
| Scheller et al., 2001 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 7 |
| Sommerlath, 1991 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 7 |
| Stein et al., 2010 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 9 |
| Vautrin and Schwartz, 2016 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 7 |
Yes = 1; no = 0; unclear = 0.
1. Is the primary hypothesis/aim/objective of the study to evaluate the prevalence of radiographic and/or symptomatic knee osteoarthritis in people with meniscectomy?
2. Are the main outcomes to be measured clearly described in the introduction or methods section?
3. Are the characteristics of the patients included in the study clearly described?
4. Is the sample of interest clearly described?
5. Are the distributions of principal confounders in each group of subjects to be compared clearly described?
6. Are the main findings of the study clearly described?
7. Was the sample size included in the analysis adequate, and was the dropout rate okay?
8. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?
9. Were the main outcome measures used accurate (valid and reliable)?
10. Was an acceptable case definition used in the study?
11. Was the same data collection used for all subjects?
12. Was the person(s) scoring the radiographs described and suitably qualified?
Results of Radiographic Tibiofemoral Osteoarthritis
| Study | Participants With APM (Analyzed) | Participants With OA Following APM | Prevalence of OA Following APM | Comparison | Participants in CG | Participants With OA in CG | Prevalence of OA in CG |
|---|---|---|---|---|---|---|---|
| 5 y to <10 y | |||||||
| Benedetto and Rangger, 1993 | 87 | 20 | 23% | NA | |||
| Bolano and Grana, 1993 | 50 (29) | 18 | 62% | NA | |||
| Bonneux and Vandekerckhove, 2002 | 29 | 26 | 90% | Contralateral knee | 29 | 5 | 17.2% |
| Fauno and Nielsen, 1992 | 136 | 72 | 53% | Contralateral knee | 136 | 30 | 22.1% |
| Han et al., 2010 | 46 | 16 | 35% | NA | |||
| Jaureguito et al., 1995 | 31 | 17 | 55% | Contralateral knee | 31 | 14 | 44% |
| Kim et al., 2020 | 114 | 69 | 60.5% | NA | |||
| Lamplot et al., 2019 | 44 (32) | 16 | 50% | Contralateral knee | 44 (32) | 6 | 20% |
| Lizaur-Utrilla et al., 2019 | 258 | 136 | 52.7% | NA | |||
| Longo et al., 2019 | 57 | 36 | 62.7% | Contralateral knee | 57 (46) | 13 | 28.3% |
| Scheller et al., 2001 | 75 (58) | 45 | 77.6% | Contralateral knee | 75 (58) | 42 | 72.4% |
| Sommerlath et al., 1991 | 25 | 13 | 52% | NA | |||
| Stein et al., 2010 | 20 | 12 | 60% | NA | |||
| 10 y to <15 y | |||||||
| Andersson-Molina et al., 2002 | 18 | 5 | 28% | Uninjured match controls | 36 | 4 | 11% |
| Burks et al., 1997 | 111 | 78 | 70.3% | NA | |||
| Chatain et al., 2001 | 317 (218) | 102 | 46.8% | Contralateral knee | 317 (218) | 38 | 17.5% |
| Higuchi et al., 2000 | 67 | 38 | 56.7% | Contralateral knee | 67 | 24 | 35.8% |
| Lutz et al., 2015 | 22 (21) | 21 | 100% | NA | |||
| Maletius et al., 1996 | 40 | 28 | 70% | Contralateral knee | 40 | 16 | 40% |
| Rockborn and Gillquist 1995 | 43 (33) | 20 | 60.6% | Contralateral knee | 40 (33) | 5 | 15.2% |
| ≥15 years | |||||||
| Englund and Lohmander 2004 | 48 | 25 | 52% | Uninjured match controls | 68 | 7 | 10% |
| Vautrin and Schwartz, 2016 | 34 | 20 | 57.7% | NA | |||
ACL, anterior cruciate ligament; APM, arthroscopic partial meniscectomy; CG, comparison group; NA, not available; OA, osteoarthritis.
Data are representative of ACL-normal knees.
Fig 2Prevalence of radiographic TF OA. (OA, osteoarthritis; TF, tibiofemoral.)
Fig 3Prevalence of radiographic versus symptomatic TF OA. (OA, osteoarthritis; TF, tibiofemoral.)
PRISMA 2009 Checklist
| Section/Topic | # | Checklist Item | Reported on Page # |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | Title page |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1-2 |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3-5 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 5 |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 5-7 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 7 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 8 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 8 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 8 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 7-8 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 9 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 5-7, 9-10 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 9-10 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | NA |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | NA |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | Tab 1 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 12-13 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 13-15 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | NA |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | NA |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | NA |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 16-20 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 20-22 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 22 |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | NA |
NOTE. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097. https://doi.org/10.1371/journal.pmed1000097. For more information, visit: www.prisma-statement.org.
NA, not available; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Search Strategy
| PubMed | (("meniscal repair"[All Fields]) OR ("meniscectomy"[All Fields])) AND ("osteoarthritis"[All Fields]) | 1,148 |
| Cochrane Library | "meniscectomy" in All Text OR "meniscal repair" in All Text AND "osteoarthritis" in All Text - (Word variations have been searched) | 441 |
| AMED (Ovid) | ((meniscectomy or "meniscal repair") and Osteoarthritis).af. | 386 |
| CINHAL (Ebsco) | Osteoarthritis AND ("meniscal repair" OR meniscectomy) | 2,523 |
| Pedro | meniscal repair OR meniscectomy AND osteoarthritis | 16 |
| Embase | (meniscectomy [all fields] OR 'meniscal repair' [all fields]) AND osteoarthritis [all fields] | 2,362 |
| Arthroscopyjournal.org | meniscal repair OR meniscectomy AND osteoarthritis | 1,174 |